Literature DB >> 27738792

SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Kuo-Cheng Huang1, Andrew Evans2, Bryan Donnelly3,4, Tarek A Bismar5,6,7,8.   

Abstract

SPINK1 is proposed as potential prognostic marker in prostate cancer (PCA). However, its relation to PTEN and ERG in localized PCA remains unclear. The study population consisted of two independent cohorts of men treated by radical prostatectomy for localized PCA (discovery n = 218 and validation n = 129). Patterns of association between SPINK1 and each of ERG and PTEN were evaluated by immunohistochemistry and fluorescence in situ hybridization. Associations between SPINK1 expression and various pathologic parameters and clinical outcome were also investigated. SPINK1 was expressed in 15.3 % and 10.9 % of cases in the discovery and validation cohort, respectively. SPINK expression was observed in 5.56 % of high-grade prostatic intraepithelial neoplasia and 1.1 % of adjacent morphologically benign prostatic glands. SPINK1 and ERG expression were almost exclusive, with only 1.0 % of the cases co-expressing both in the same core sample. SPINK1 interfocal and within-core heterogeneity was noted in 29.2 % and 64.6 % of cases, respectively. SPINK1 expression was not significantly associated with PTEN deletion in the two cohorts (p = 0.871 for discovery cohort and p = 0.293 for validation cohort). While SPINK1 expression did occur with hemizygous PTEN deletion, there was a complete absence of SPINK1 expression in PCA showing homozygous PTEN deletion, which was confirmed in the validation cohort (p = 0.02). Despite SPINK1's association with higher Gleason score (>7) (p = 0.02), it was not associated with other pathological parameters or biochemical recurrence post-radical prostatectomy. We documented absolute exclusivity between SPINK1 overexpression and homozygous PTEN deletion in localized PCA. SPINK1 and ERG expressions are exclusive events in PCA. SPINK1 is not of added prognostic value in localized PCA.

Entities:  

Keywords:  Biomarkers; ERG; Hemizygous; Homozygous; PTEN deletion; Progression; Prostate cancer; SPINK1

Mesh:

Substances:

Year:  2016        PMID: 27738792     DOI: 10.1007/s12253-016-0119-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  24 in total

1.  Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Authors:  Stéphane Terry; Nathalie Nicolaiew; Victor Basset; Fannie Semprez; Pascale Soyeux; Pascale Maillé; Francis Vacherot; Guillaume Ploussard; Arturo Londoño-Vallejo; Alexandre de la Taille; Yves Allory
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

2.  Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.

Authors:  Katri A Leinonen; Teemu T Tolonen; Hazel Bracken; Ulf-Håkan Stenman; Teuvo L J Tammela; Outi R Saramäki; Tapio Visakorpi
Journal:  Clin Cancer Res       Date:  2010-05-04       Impact factor: 12.531

Review 3.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

4.  Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Authors:  Tarek A Bismar; Maisa Yoshimoto; Qiuli Duan; Shuhong Liu; Kanishka Sircar; Jeremy A Squire
Journal:  Histopathology       Date:  2012-01-19       Impact factor: 5.087

Review 5.  Tumor-associated trypsin inhibitor.

Authors:  Ulf-Håkan Stenman
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

6.  The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.

Authors:  Kuo-Cheng Huang; Mohammed Alshalalfa; Samar A Hegazy; Michael Dolph; Bryan Donnelly; Tarek A Bismar
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

7.  Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Authors:  James D Brooks; Wei Wei; Sarah Hawley; Heidi Auman; Lisa Newcomb; Hilary Boyer; Ladan Fazli; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Ziding Feng; Jesse K McKenney
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

8.  Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Authors:  B Gumuskaya; B Gurel; H Fedor; H-L Tan; C A Weier; J L Hicks; M C Haffner; T L Lotan; A M De Marzo
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-04-02       Impact factor: 5.554

9.  HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Authors:  Steven C Smith; Nallasivam Palanisamy; Kimberly A Zuhlke; Anna M Johnson; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju; Kathleen A Cooney; Scott A Tomlins
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

10.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

View more
  3 in total

1.  Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Authors:  Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

2.  The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis.

Authors:  Xingming Zhang; Xiaoxue Yin; Pengfei Shen; Guangxi Sun; Yaojing Yang; Jiandong Liu; Ni Chen; Hao Zeng
Journal:  Onco Targets Ther       Date:  2017-06-22       Impact factor: 4.147

Review 3.  Functional Roles of SPINK1 in Cancers.

Authors:  Tsung-Chieh Lin
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.